Wound Week - September 20-24, Philadelphia, PA
Discover the future of wound care at APWCA 2023
Experience our technology at APWCA Wound Week
Attend the APWCA Wound Week 2023 and explore our innovative, rigorously designed and patented solution for foot ulcers. The unique process provides autologous wound management at the point of care, meaning a 100% unique patch prepared from the patient’s own blood.
3C PATCH® IS EVIDENCE BASED AND IWGDF RECOMMENDED
3C Patch® is an autologous product, meaning it is made from the patient`s own blood.
The International Working Group on the Diabetic Foot (IWGDF) now recommends the use of Reapplix’s technology, the 3C Patch®, an autologous combined leucocyte, platelet and fibrin, as an adjunctive treatment..
TRULY AUTOLOGOUS WITH NO REAGENTS OR ADDITIVES
3C PATCH® SYSTEM
The 3C Patch® System contains rigorously designed and patented components. The unique process provides autologous wound management at the point of care, meaning a 100% unique patch prepared from the patient’s own blood:
CENTRIFUGATION
The proprietary high speed centrifugation is a unique part of the patented 3C Patch® Process